Evidence map›Paper›PMID 33960011›Full record

ArticleJournal of clinical laboratory analysis2021

Non-invasive urine markers for the differentiation between RCCs and oncocytoma.

Melanie von Brandenstein, Jan Herden, Barbara Köditz, Manuel Huerta, Tim Nestler, Axel Heidenreich, Jochen W U Fries

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Melanie von BrandensteinDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-1499-7644
Jan HerdenDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Barbara KöditzDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Manuel HuertaDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tim NestlerDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Axel HeidenreichDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jochen W U FriesDepartment of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
University of Cologne · DE

Funding

EFRE NRW-Förderwettbewerb NRW-Patent-ValidierungWIPANO-Wissens- und Technologietransfer durch Patente und Normen (Mxi-2)
6 · The paper itself

Abstract

backgroundRecently, our group showed that Vim3 is overexpressed in tissue samples of renal oncocytomas and Mxi-2 in clear cell renal carcinoma (ccRCC). The mechanism leading to the truncation of both proteins is known and involves with two miRs, both detectable in urine. Since the analysis of miRs is time-consuming, our aim was to identify the truncated proteins in urine instead. Furthermore, urine samples from small renal masses (SRMs) (n = 45, <4 cm) were analyzed to get a pre-surgical differentiation of the cancer subtypes.

methodsUrines were accessed from the urological biobank (n = 350). Proteins were isolated from urine samples, and Western blots were performed. Each sample was analyzed with ELISA for the expression of Vim3 and Mxi-2. A lateral flow assay was established. For the detection of SRMs, the miRs were isolated and qRT-PCR was performed.

resultsA significant increase of Vim3 in urines from patients with oncocytoma (n = 20) was detectable with ELISA compared to all other subtypes of RCCs (chromophobe (n = 50), papillary (n = 40), ccRCC (n = 200), and controls (n = 40) (***p < 0.0001)). Mxi-2 was predominantly overexpressed in ccRCCs (***p < 0.0001). Lateral flow assay of Vim3 and Mxi-2 shows two bands in the case of oncocytoma and ccRCC indicating the specificity of this test. For SRMs, an overexpression of miR-15a/Mxi2 was detectable in urine samples from ccRCC and chromoRCC patients. In contrast to that, miR-498/Vim3 were predominantly overexpressed in oncocytoma patients.

conclusionBoth proteins (Vim3 and Mxi-2) were detectable in patients' urines and can be used for the non-invasive differentiation of kidney cancers.

Indexed as

Adenoma, OxyphilicBiomarkers, TumorCarcinoma, Renal CellDiagnosis, DifferentialFemaleHumansKidney NeoplasmsMaleMiddle AgedBiomarkers, TumorELISAkidney cancerMxi-2small renal cancerurine biomarkerVim3

Identifiers

PMID33960011
PMCPMC8128285
OpenAlexW3157107717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.